COVID-19 vaccine developed by Oxford University develops promising immune response in human trial

A potential COVID-19 vaccine developed by Oxford University has reportedly produced a promising immune response in a large, early-stage human trial.
According to newly released data published Monday in the medical journal, The Lancet, 100 percent of the participants in the trial developed neutralizing antibodies.
The trial was carried out in April on some 1-thousand people between the ages of 18 and 55 in the UK.
Researchers explained that the vaccine, being jointly developed with pharmaceutical giant AstraZeneca, also produced killer T-cells that help patients combat the infection by attacking the infected cells.
The World Health Organization welcomed the news, but warned that there's a long road ahead

We do welcome the study and congratulate our colleagues at the Oxford University's General Institute and the Oxford Vaccine Group. And and obviously our colleagues at AstraZeneca for getting this data out there But again, there is a long way to go. These are phase one studies. We now need to move into larger scale, real world trials."

There was also positive news on vaccine development in other parts of the world, with America's Pfizer and Germany's BioNTech successfully immunizing their participants.
The trial carried out on 60 adults in Germany proved to be safe and successfully induced an immune response.
Such a response echoed results of a similar test conducted in the U.S.
Pfizer and BioNTech now plan to begin testing on some 30-thousand volunteers this month to prove the efficacy of their vaccine.
Kim Hyo-sun, Arirang News.